跳至主要内容
临床试验/ACTRN12606000275561
ACTRN12606000275561已完成不适用

Pharmacokinetics and pharmacogenetics of methotrexate (MTX) in rheumatoid arthritis (RA)

isa Stamp0 个研究点目标入组 200 人开始时间: 2006年7月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 ot stated(—)
性别
All

入选标准

  • I. Patients with RA (ARA ’87 Criteria, (Arnett et al. 1988). II Methotrexate therapy either as monotherapy or combination therapy for at least three months. The dose of methotrexate must be at a stable dose of 5-20 mg/weekly over the preceding four weeks.III Patients whom the treating Rheumatologist wishes to start or stop MTX.IV Able and willing to give written informed consent and to comply with the requirements of the study.

排除标准

  • I. A change in dose or introduction of another disease modifying anti-rheumatic drug, nonsteroidal anti-inflammatory agent or oral steroid within the preceding month.II. Intra-articular steroid injections within one month prior to enrolment.III. Evidence of serious uncontrolled chronic concomitant disease.

研究者

发起方
isa Stamp

相似试验